Itamar-Medical (TASE: ITMR), the world's leader of non-invasive devices for diagnosis of cardiovascular health, announced achievement of the next milestone of the international pharmaceutical company, Roche, to further develop the EndoPAT technology for pre-clinical trials. This is a continuation of the original announcement from December 2010.
The device developed will enable pharmaceutical companies in general to potentially integrate EndoPAT into a large number of drug development projects at a very early drug development stage.
Itamar's EndoPAT technology serves as a vital, non-invasive diagnostic tool for measuring endothelial dysfunction - the early stage of arteriosclerosis in humans.
"Further to our work with Roche, this continued development strengthens Itamar-Medical's strategic direction that the EndoPAT can support translational medicine a further step towards the important trend of Personalized Medicine using Companion Diagnostics," said Dr. Dov Rubin, President and CEO of Itamar-Medical Ltd.
Dr. Koby Sheffy, Senior Vice President of Technology at Itamar-Medical added, "This advanced development positions the EndoPAT technology as a preferred technology in the development of cardiovascular drugs, from the early animal model stage and over the continued various development stages with humans."
Revolutionizing diabetes management with reliable blood glucose monitoring without finger pricking